A representation of a man holding gains in his palm. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Hastings Technology Metals (ASX:HAS) announced on Wednesday it will execute a renounceable rights issue to raise $22M.

New shares will be priced at 36cps with a 1-for-3 attaching option at 50cps two years post issue.

Eligible shareholders may apply for new shares in addition to their entitlement on the same terms where shortfall is available.

“Under the Rights Issue, eligible existing shareholders are invited to subscribe for nine (9) new fully paid ordinary shares (“New Shares”) for every 20 existing Shares held at the Record Date of Wednesday, 3 April 2024,” the company specified.

Hastings was quick to point out on Wednesday that its own C-Suite will participate in the rights issue.

The ultimate outcome of the $22M raise is for working capital to continue development of its Yangibana REE Project, including the completion of project funding.

The issue is partially underwritten.

“All of the Company’s Board and senior management team intend to take up their entitlement in the Rights Issue, underlining our conviction in the Yangibana Project’s potential to become a world-class rare earth operation,” Hastings Chair Charles Lew said.

“We are pleased to be able to offer our existing shareholders the opportunity to participate in this current funding round which will facilitate the continuation of our project development workstreams for the Yangibana Project.”

HAS last traded at 49.5cps.

HAS by the numbers
More From The Market Online
Market Close Graphic

ASX Market Close: Another reversal as just-green Oz markets ignore US dive | Jan 3, 2024

The Aussie bourse has defied morning expectations for the second time in as many days, closing out all but flat with a 0.
A Red Sky Energy rig out in the ocean.

Red Sky Energy bleeds more than 18% after ‘landmark’ Angola block entry

Red Sky Energy was ready to pop champagne after being awarded 35% in a "transformative" Angola…
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
A market trading board with ASX marked on the side.

‘Shine a light’: ASX to get more aggressive on companies ‘not up to scratch’ on disclosures

The Australian Securities Exchange (ASX:ASX) will be taking poor disclosure from market-listed companies far more seriously through this next